Abstract
Braf mutation is described in approximately 50% of cutaneous melanoma and selective inhibition of this mutation is manifested by the extension of progression free survival and overall survival. Dabrafenib demonstrates very good peffomance in PFS and OS in patients with BRAF positive metastatic melanoma.